A retrospective data collection study of type-2 diabetic patients in India

Active, not recruiting

• Conditions: Type 2 diabetes mellitus without complications,

• Registration Number: CTRI/2022/01/039251
• Lead Sponsor: Ragus Healthcare Private Limited

Brief Summary

The prevalence of type 2 diabetes is expanding exponentially in the world especially in developing countries. India is the diabetes capital of the world with an alarming increase of the condition across all age groups. According to the latest International Diabetes Federation’s Diabetes Atlas 2021, in southeast asia alone: 1 in 11 adults (90 million) are living with diabetes. The number of adults with diabetes is expected to reach 113 million by 2030 and 151 million by 2045. 747,000 deaths were caused by diabetes in 2021. The ability of an individual living with diabetes to have human-to-human contact with their healthcare provider is not keeping pace with the number of people developing diabetes This study has been designed to develop a better understanding around the variability of Hb1Ac, fasting blood sugar, weight, and medication in type-2 diabetic patients and understand their correlations.

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2022-08-01
• Study Start: 2022-10-01

Recruitment & Eligibility

• Status: Closed to Recruitment of Participants
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Male or female patients with Type 2 diabetes mellitus of 18 to 70 years of age (both inclusive) 2.
• Patients with HbA1c value between 6.5% and 9.0% (both inclusive) 3.
• The subject records to be captured must not be more than 12 months old.

Exclusion Criteria

• Subject with Type-1 diabetes 2.
• HbA1c < 6.5% 3.
• Diabetic complications (Neuropathy, Nephropathy, retinopathy and amputation).

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To collect retrospective data on the following parameters at two different time-points at an interval of 90 days (±10 days):	Baseline and Day 90
a) Fasting Blood Sugar (FBS)	Baseline and Day 90
b) HbA1c	Baseline and Day 90
c) Medications	Baseline and Day 90
d) Weight	Baseline and Day 90

Secondary Outcome Measures

Name	Time	Method
NA	NA

Trial Locations

Locations (1)

DIVINE Multispecialty Hospital and Cancer Centre; 🇮🇳 North, DELHI, India

DIVINE Multispecialty Hospital and Cancer Centre

🇮🇳North, DELHI, India

Dr Rohit jain

Principal investigator

9212410444

rohitjain4783@gmail.com